101.82 USD
+0.44 (+0.43%)
101.82 USD
0 (0%)
Overall EXAS gets a fundamental rating of 4 out of 10. We evaluated EXAS against 531 industry peers in the Biotechnology industry. The financial health of EXAS is average, but there are quite some concerns on its profitability. EXAS has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year EXAS has reported negative net income.
In the past year EXAS had a positive cash flow from operations.
EXAS had negative earnings in each of the past 5 years.
In multiple years EXAS reported negative operating cash flow during the last 5 years.
1.2 Ratios
EXAS has a Return On Assets of -16.72%. This is in the better half of the industry: EXAS outperforms 78.64% of its industry peers.
With a decent Return On Equity value of -39.44%, EXAS is doing good in the industry, outperforming 71.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.72% | ||
| ROE | -39.44% | ||
| ROIC | N/A |
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EXAS has a Gross Margin of 67.37%. This is amongst the best in the industry. EXAS outperforms 80.34% of its industry peers.
EXAS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EXAS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
2. Health
2.1 Basic Checks
EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EXAS has more shares outstanding
Compared to 5 years ago, EXAS has more shares outstanding
Compared to 1 year ago, EXAS has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.94 indicates that EXAS is not a great score, but indicates only limited risk for bankruptcy at the moment.
EXAS has a better Altman-Z score (2.94) than 68.62% of its industry peers.
EXAS has a debt to FCF ratio of 9.47. This is a negative value and a sign of low solvency as EXAS would need 9.47 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 9.47, EXAS belongs to the top of the industry, outperforming 90.17% of the companies in the same industry.
EXAS has a Debt/Equity ratio of 0.93. This is a neutral value indicating EXAS is somewhat dependend on debt financing.
EXAS has a Debt to Equity ratio of 0.93. This is in the lower half of the industry: EXAS underperforms 76.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.93 | ||
| Debt/FCF | 9.47 | ||
| Altman-Z | 2.94 |
ROIC/WACCN/A
WACC8.05%
2.3 Liquidity
A Current Ratio of 2.72 indicates that EXAS has no problem at all paying its short term obligations.
With a Current ratio value of 2.72, EXAS is not doing good in the industry: 68.81% of the companies in the same industry are doing better.
EXAS has a Quick Ratio of 2.44. This indicates that EXAS is financially healthy and has no problem in meeting its short term obligations.
EXAS's Quick ratio of 2.44 is on the low side compared to the rest of the industry. EXAS is outperformed by 69.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.44 |
3. Growth
3.1 Past
The earnings per share for EXAS have decreased strongly by -354.70% in the last year.
EXAS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.47%.
Measured over the past years, EXAS shows a very strong growth in Revenue. The Revenue has been growing by 25.78% on average per year.
EPS 1Y (TTM)-354.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.38%
Revenue 1Y (TTM)14.47%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%20.05%
3.2 Future
EXAS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.50% yearly.
The Revenue is expected to grow by 11.01% on average over the next years. This is quite good.
EPS Next Y87.09%
EPS Next 2Y43.47%
EPS Next 3Y30.54%
EPS Next 5Y21.5%
Revenue Next Year17.56%
Revenue Next 2Y15.52%
Revenue Next 3Y14.38%
Revenue Next 5Y11.01%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for EXAS. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 313.03, EXAS can be considered very expensive at the moment.
EXAS's Price/Forward Earnings ratio is rather cheap when compared to the industry. EXAS is cheaper than 87.52% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.83, EXAS is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 313.03 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EXAS indicates a rather cheap valuation: EXAS is cheaper than 88.85% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of EXAS indicates a rather cheap valuation: EXAS is cheaper than 91.87% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 78.2 | ||
| EV/EBITDA | 321.78 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates EXAS does not grow enough to justify the current Price/Earnings ratio.
EXAS's earnings are expected to grow with 30.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.47%
EPS Next 3Y30.54%
5. Dividend
5.1 Amount
EXAS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
101.82
+0.44 (+0.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners94.55%
Inst Owner Change2.4%
Ins Owners0.85%
Ins Owner Change-0.68%
Market Cap19.32B
Revenue(TTM)3.08B
Net Income(TTM)-986.58M
Analysts68.28
Price Target100.65 (-1.15%)
Short Float %2.73%
Short Ratio0.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.24%
Min EPS beat(2)-40.06%
Max EPS beat(2)94.53%
EPS beat(4)1
Avg EPS beat(4)-344.13%
Min EPS beat(4)-1391.93%
Max EPS beat(4)94.53%
EPS beat(8)4
Avg EPS beat(8)-160.89%
EPS beat(12)8
Avg EPS beat(12)-92.72%
EPS beat(16)11
Avg EPS beat(16)-67.39%
Revenue beat(2)2
Avg Revenue beat(2)2.8%
Min Revenue beat(2)2.65%
Max Revenue beat(2)2.95%
Revenue beat(4)3
Avg Revenue beat(4)1.49%
Min Revenue beat(4)-0.27%
Max Revenue beat(4)2.95%
Revenue beat(8)3
Avg Revenue beat(8)0.13%
Revenue beat(12)6
Avg Revenue beat(12)1.15%
Revenue beat(16)10
Avg Revenue beat(16)1.59%
PT rev (1m)41.34%
PT rev (3m)53.54%
EPS NQ rev (1m)-1255.6%
EPS NQ rev (3m)-2135.44%
EPS NY rev (1m)-11.46%
EPS NY rev (3m)-20.43%
Revenue NQ rev (1m)1.07%
Revenue NQ rev (3m)4.15%
Revenue NY rev (1m)2.33%
Revenue NY rev (3m)2.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 313.03 | ||
| P/S | 6.27 | ||
| P/FCF | 78.2 | ||
| P/OCF | 49.95 | ||
| P/B | 7.72 | ||
| P/tB | N/A | ||
| EV/EBITDA | 321.78 |
EPS(TTM)-5.32
EYN/A
EPS(NY)0.33
Fwd EY0.32%
FCF(TTM)1.3
FCFY1.28%
OCF(TTM)2.04
OCFY2%
SpS16.24
BVpS13.18
TBVpS-4.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.72% | ||
| ROE | -39.44% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.37% | ||
| FCFM | 8.02% |
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
F-Score4
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.93 | ||
| Debt/FCF | 9.47 | ||
| Debt/EBITDA | 36.88 | ||
| Cap/Depr | 63.99% | ||
| Cap/Sales | 4.53% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 611.3% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.44 | ||
| Altman-Z | 2.94 |
F-Score4
WACC8.05%
ROIC/WACCN/A
Cap/Depr(3y)84.38%
Cap/Depr(5y)130.41%
Cap/Sales(3y)7.28%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-354.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.38%
EPS Next Y87.09%
EPS Next 2Y43.47%
EPS Next 3Y30.54%
EPS Next 5Y21.5%
Revenue 1Y (TTM)14.47%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%20.05%
Revenue Next Year17.56%
Revenue Next 2Y15.52%
Revenue Next 3Y14.38%
Revenue Next 5Y11.01%
EBIT growth 1Y25.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year328.14%
EBIT Next 3Y82.51%
EBIT Next 5Y52.71%
FCF growth 1Y1146.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y179.09%
OCF growth 3YN/A
OCF growth 5YN/A
EXACT SCIENCES CORP / EXAS FAQ
What is the fundamental rating for EXAS stock?
ChartMill assigns a fundamental rating of 4 / 10 to EXAS.
Can you provide the valuation status for EXACT SCIENCES CORP?
ChartMill assigns a valuation rating of 4 / 10 to EXACT SCIENCES CORP (EXAS). This can be considered as Fairly Valued.
How profitable is EXACT SCIENCES CORP (EXAS) stock?
EXACT SCIENCES CORP (EXAS) has a profitability rating of 2 / 10.